Leading co-authors of an investigation regarding this subject are doctors Shamini Jain and Paul Mills. The first comes from the Division of Cancer Prevention and Control Research within the University of California, Los Angeles and the latter is a doctor in the University of California`s Department of Psychiatry. Along with the Moores Comprehensive Cancer Center from San Diego, United States, the two released their research findings regarding the bio-field treatments on the Internet website of the Springer’s International Journal of Behavioral Medicine.

There is an important number of people suffering from various conditions who use bio-field based treatments such as: healing touch, Reiki and therapeutic touch. However, the efficacy of these treatments has not been proven. These therapeutic treatments date millennia back when they were used for counteracting various physical and mental diseases in numerous cultural clusters. Nowadays, they are under the magnifier as Western researchers are trying to discover just how efficient they are in counteracting various conditions.

Doctors Shamini Jain and Paul Mills underwent a study comprising clinical trials which summed up a number of 66. They focused on the bio-field related treatments associated with therapies for various patients coming from different cultures and suffering from different conditions. The investigators focused on just how clear and convincing the effectiveness of this type of treatment was. The group of researchers found out that all the studies released on the bio-field therapies are somehow of middle quality related to the scientific evidence.

Considering this findings, the team of investigators discovered hard proves that the bio-field based treatments decrease the degree of pain in people belonging to the non-hospitalized population and mild proves that these therapies are efficient regarding the decreasing degree of pain in people admitted to hospitals and patients suffering from malignant tumors.

Mild proves regarding the bio-field therapies exist related to the aggressive behavior of people suffering from dementia and the efficiency of these treatments in diminishing the anxiety state of people admitted to hospitals. The group of investigators did not find any link between the effectiveness of the bio-field treatments and conditions such as fatigue and the life quality of people suffering from malignant tumors, overall degree of pain decrease and anxiety counteracting in people developing cardiovascular conditions.

The team of researchers state that there is an increasing need to investigate further this subject in a very qualitative manner and also recommend come areas that could host these investigations. In addition, they state that in order for patients to be better informed regarding the possible advantages and disadvantages of bio-field based therapies, physicians and researchers concerned with the behavioral medicine have to acquire a good understanding of this subject. This means that the doctors and scientists have to be well informed regarding bio-field based therapies and take a closer look at practice, theory and studies focusing on this matter.

The investigation was released in the Cancer Research journal in its October edition. The investigators from the University of Texas Southwestern Medical Center discovered that if they gave the mice the BEZ235 medication prior to undergoing harmless radiation in order to counteract the cancerous cell development of DNA, the BEZ235 would counteract the activity of the PI3K protein which typically acts as a guardian of the tumor cells. This protein maintains the cancerous cells in life in the moment they are attacked and try to heal their broken DNA.

Besides the leading author, the team of investigators from the University of Texas comprised: doctor Erik Bey from the Harold C. Simmons Comprehensive Cancer Center, doctor Andrea Rabellino, doctor Katja Schuster, doctor Adi Gazdar, professor within the University of Texas Southwestern, Jake Hamon from the Center for Therapeutic Oncology Research, doctor David Boothman from the Simmons Comprehensive Cancer, researchers coming from the University of Camerino in Italy and Novartis Pharma in Switzerland. Their investigation was financed by funds coming from National Institutes of Health, American Cancer Society, Concern Foundation, Gibson Foundation, Leukemia of Texas, United States Department of Energy and the American Italian Cancer Foundation.

The scientists observed this treatment opportunity in mice that underwent a transplant process with non-small cell lung cancer tumors from human beings.

During their observation process, the researchers discovered that the malignant tumors developing in the mice which were treated with just the BEZ235 has a decrease in size compared to those affecting mice which were not undergoing any type of treatments. Even though the malignant tumors did not grow in size, their life was not ended by administering the specific medication.

On the other hand, mice undergoing the BEZ235 treatment combined with low-dose radiation recorded many cases of total elimination of the malignant tumors.

The leading investigator was doctor Pier Paolo Scaglioni who is assistant professor of the internal medicine department within the University of Texas Southwestern. He stated that the findings of his research team regarding the combination of medication and low-dose radiation may prove to become an efficient treatment for counteracting non-small cell lung cancer in human beings.

The non-small cell lung cancer represents one of the main causes of cancer connected mortality on the whole Globe. The malignant cells usually favor transformations in the K-RAS which is a gene. People suffering from mutations of the K-RAS usually present an increased resistance to therapies comprising irradiation. This is the cause for which their life perspectives are unfavorable.

The K-RAS transformations trigger the networks or different pathways of various proteins that act as signals to activate. This signaling represents a key element in the development and growth of a malignant tumor. The PI3K represents just one of these proteins. At the moment of activation, it acts as a guardian which aids the cells in maintaining living functions even after their DNA was damaged and they try to heal it.

Some of the elements forming the signal networks comprising also the PI3K protein have been explored as various medication targets for counteracting malignant tumors. The clinical tested medication BEZ235 has been recently in experiments comprising clinical tests for counteracting the activity of the PI3K and the mTOR which represents a signaling protein, also.

As the leading investigator states there is no efficient treatment counteracting the non-small cell lung cancer which hosts transformations of the K-RAS.

Medical doctor Pier Paolo Scaglioni conducted the first tests in order to identify the efficacy of the BEZ235 drug and thus, they tested it alone. The team of investigators discovered that the BEZ235 stops the evolution and growth of the lung cancer malignant cells that were developed in the laboratory and the malignant lung cells that affect the mice.

As the leading author of this first research, doctor Georgia Konstantinidou states the findings of the investigators were shocking. However, they strived to discover a way for a faster malignant cell deterioration. They found put that by combining the tested medication with low-dose radiation, the success of their mission was assured. Doctor Georgia Konstantinidou is a post-doctoral scientist within the University of Texas Southwestern.

Doctor Pier Paolo Scaglioni`s research group observed that the malignant cells which were treated with the BEZ235 medication and low-dosed irradiation. The latter triggered slight breaks in the cellular genetic material but did not managed to affect them in a more effective way in order to destroy them. At the moment the DNA of the cell is broken, the malignant cells are aided by the PI3K signaling network in order to assure the cancer cell`s survival while it is healing its genetic material.

The team of investigators explained that the malignant cells needed the PI3K signaling pathway to assure they remain alive and without the protein`s response they were prone to die. This is why in the moment the scientists administered the BEZ235 medication it stopped the action of the PI3K protein and this means that the non-small cell lung cancer cells were starting to die.

As the leading author of the research explains the future stage of the study is that of administering the BEZ235 medication or similar drugs in clinical tests against the non-small cell lung suffering human beings. This could also be applied in clinical trials comprising people suffering from other types of malignant cells such as pancreatic, colon and thyroid cancers. There are the same with the non-small cell lung due to the fact that the PI3K signaling network also acts as an important agent in the malignant cells` evolution.

This environmental report is just a part of the process of taking care of the continuous and newly discovered problems regarding the pollutant agents of the environment and cancer. Moreover, the scope of the report is to shed more light on the principles, mission, values, objectives and various roles of the American Cancer Society on issues such as those mentioned before: pollution and malignant tumors prevention.

As the co-chair of the subcommittee and chairman of the Department of Preventive Medicine within the Keck School of Medicine of University of Southern California, medical doctor Jonathan Samet explains the problems regarding the environmental pollution agents affecting the air, water, food and thus, customer products represent issues on general public care and high unknowns. He also adds that their report aims to put the pollution agents of the environment in a greater relationship with preventing malignant tumors. The relationship focuses on reducing the smoking habit of the population, improving nutritional behavior, increasing the physical activities, maintaining a proper body weight and come up with vaccines that counteract the infections which may cause cancers.

The other co-chair of the subcommittee is also volunteer president of the American Cancer Society. Her name is Elizabeth “Terry” T.H. Fontham and she stated that the exposure levels of the population to chemical and pollution agents affecting the environment are much lower than the levels linked to the showed predisposition to developing malignant tumors in the jobs people have and other daily settings. However, the concern raised by the low exposure levels has to do with the fact that the number and types of pollution substances are increasing and may prove in the future to get out of the population`s control. In addition, the problems related to the fact that even low exposure levels bring some contribution to the cancer developing cases cause more reasons for distress considering the high number of persons who are daily exposed to the environmental pollutants.

The subcommittee`s report states that the scientific problems related to the exposure of people to the environmental pollutants represent complex issues just like increase in the number of landscape technologies which are utilized to analyze the chemical carcinogenicity. In spite of the capability of the nowadays tools used to identify and categorize proves for carcinogenicity, the subcommittee`s article states that there exist three main problems which constrain them from using them because there is a limited quantity of resources which are allotted to function those specific systems and from a scientific point of view, the environmental problems are complex and uncertain.

The report`s concerns about cancer vary and are related to malignant tumors prevention. There is a high need for new stratagems related to the tests done to evaluate the environment`s toxicity, comprising also the evaluation of carcinogenicity. These new strategies could be incorporated in such a manner as to assure a more efficient and effective screening process of a higher number of chemical agents which affect people daily. In addition, exposure to occupational and community settings should be regulated by some standards. The subcommittee draws attention on the need to support investigations aimed at identifying and decreasing the number of hazards provoked by carcinogens. Furthermore, the institutions that determine and implement standards for the environment must meet proper financing and appropriate technology in order to be near the scientific evolution and upgrade their set standards according to the new available data.

Even though some exposure cannot be avoided, this type of exposure must be somehow diminished and even stopped in the cases where it is possible to do so. In addition, the population must receive information about these matters in order to know their health status and risk of cancer or other diseases. Last, but not least, the media communication must make people aware of the situation of the exposure in an accurate manner and not to exaggerate or diminish the importance and level of environmental pollution factors.

The subcommittee’s report states that in order to create and implement this new initiative in order to assure the acquiring of more knowledge regarding the association between the levels of exposure to environmental pollution agents and the predisposition to various types of cancers, the American Cancer Society is going to further develop its long-run commitment to preventing malignant tumors. In addition, the American Cancer Society is also keen on studying these problems more thorough in order to discover new ways in which the initiative could bring more benefits in an effective and efficient manner.

Nonetheless, the WHI (Women’s Health Initiative) which is an important research showed that using the hormone replacement therapy for older women who were at menopause several predispositions for various outcomes would increase. However, this therapy did not increase the mortality rate. The research was released in the year 2002. This investigation and its outcomes generated a wide debate related to the possible advantages and disadvantages of using the hormone replacement therapy.

A recent study released in The American Journal of Medicine in its November edition comprised an investigation which comprised a meta-analysis of the public information. This was done by utilizing Bayesian methodology and has as result the fact that using the hormone replacement therapy is prone to diminish the mortality rates among females who reached menopause at a younger age.

The Bayesian method utilizes past data which is upgraded by new available knowledge in order to infer about a certain outcome from a statistical point of view. The scientists evaluated the outcomes of nineteen random tests which comprised data regarding the age of the women coming from the Women’s Health Initiative. The subjects were formed by 16,000 women who reached menopause at a younger age. The group`s average age was of 55 years and summed up 83,000 human being years. The researchers discovered that the group`s risk of death was of 0.73.

Afterward the investigators added to the study information coming from eight evaluation researches. After computing the relative death risk, they discovered that it was 0.72. After this step, the scientists utilized the Bayesian analysis method to summarize the information they had obtained earlier. During this process they found out that the possibility of a death benefit in the studied patients was 1.0. This figure means that the possibility of the theory that the hormone treatment decreased total death rate in women who reached menopause at a younger age is 1.

The leading author of the study was medical doctor Shelley Salpeter. She said that her team`s discoveries had to be evaluated from the possible advantages and disadvantages of the hormone replacement therapy point of view. The public data which they had showed that the hormone replacement therapy used in treating women who reached menopause at a younger age enhanced the females` predisposition of developing breast malignant tumors or pulmonary embolism, but reduced the predisposition of cardiovascular problems, developing colon malignant tumors and hip fractures.

The advantage of reducing the risk of cardiovascular problems came as a result of a slight increase in the stroke rates but a much higher decrease in the problems related to coronary heart illnesses. The whole death benefit brought to women who reached menopause at a younger age observed during the random tests and evaluation research showed that the decrease in problems ranging from heart disease, fracture, and colon cancer was much greater than the increase in the number of death provoked by breast malignant tumors, pulmonary embolism and strokes. Moreover, the hormone replacement therapy used for younger women brought to them an enhancement in their life quality measurements, at least in the period after concluding this type of treatment.

The investigation of the Swedish researchers is released in the Arthritis & Rheumatism in the November edition which is a journal of the American College of Rheumatology by Wiley-Blackwell.

The tumor necrosis factor is a solution produced by the body`s immune system cells entitled cytokine. This substance has the role of regulator of the immune system and plays a great part in the inflammation process. Tumor necrosis factor inhibitors also known as blockers of the tumor necrosis factor represent a group of treatments that is utilized in counteracting swellings in chronic swellings such as the rheumatoid arthritis. The standard immunosuppressant medications and those comprised in the investigation are Enbrel®, Remicade® and HumiraTM. Due to the fact that these treatments are utilized in order to counteract the chronic swelling diseases, the long-run inhibition of the tumor necrosis factor determines debates on the enhanced predisposition to cancer or various infections.

The Swedish investigation represents one of the biggest and long lasting evaluations of the population in verifying the predisposition of developing malignant tumors linked to treatments that comprise immunosuppressive medications. The research incorporated information coming from various Swedish databases such as the Cancer Register, the Biologics Register and the Early RA Register.

The group of scientists observed and evaluated the data coming from 6,366 people who began anti- tumor necrosis factor treatment on a period ranging between January 1999 and July 2006. The information coming from patients who underwent tumor necrosis factor inhibiting therapies was later compared with some other groups of people who suffered from rheumatoid arthritis. These groups comprised 61,160 people who did not take any kind of drugs, 4,015 patients using the gold standard rheumatoid arthritis therapy entitled methotrexate and 4,015 individuals who took combinations of anti- rheumatoid arthritis medications that were known to modify the illness but different from the drugs inhibiting the tumor necrosis factor.

The outcome of the large investigation was that 240 first main cancers were diagnosed during the 25,693 human-being years of tracking in the people who underwent anti- tumor necrosis factor treatments who did not present any history of malignant tumors at the outbreak of the immunosuppressant drug therapy. In comparison with the bigger national rheumatoid arthritis group who did not get tumor necrosis factor inhibitor medications or who had developed malignant tumors in the past, the relative predisposition to develop cancer for patients who underwent anti- tumor necrosis factor treatments was 1.00 and did not change for the persons who took immunosuppressant medications for even six years.

As the leading investigator states their research pointed out the overall predisposition to cancer was the same for people who developed rheumatoid arthritis and were currently undergoing immunosuppressant treatments and those patients who did not take that type of medication in counteracting their illness. In addition, doctor Askling states that there are some uncertainties that remain under the sing of the doubt and recommends vigilance in these treatments in order to assure that nothing goes wrong.

The rheumatoid arthritis represents an autoimmune illness that has as symptoms chronic swelling of the joint, joint tissues and other organs. The RA is one of the most widely spread variant of swelling arthritis. Statistics released in 2004 by WHO (World Health Organization) stated that approximately 23.7 million individuals all over the Globe, from which 1.3 adults from the United States, suffered from rheumatoid arthritis. 75 percent of the 23.7 million cases represented the female gender.

An investigation set up on the “Asian paradox” was released in the World Journal of Gastroenterology in this year`s October edition. The investigation was led by medical doctor Murdani Abdullah who activates in the Division of Gastroenterology, Department of Internal Medicine within the University of Indonesia. The research started from an earlier concept developed by P. Correa. This is concerned with the fact that there are some changes in the mucosa triggered in a cascade manner which are triggered either by acute or chronic gastritis and develop into gastric malignant tumors.

The variations in the way Helicobacter pylori affects the gastric tract and produces gastritis might provide the explanations of the variety of gastric malignant tumors incidence between Japan and Indonesia, for example. Earlier research never took a closer eye at these transformations of the gastric mucosa which later developed into gastric cancer.

The recent investigation strives to observe the changes that occur in the gastric mucosa at the time when it is infected with Helicobacter pylori and develops gastric malignant tumors. The transformations of the gastric mucosa were observed in two Asian countries that present the “Asian paradox”: Japan and Indonesia.

Starting with the year 1998, 42 sick people from the Yamanashi Medical University Hospital located in Koufu and 125 patients from the Metropolitan Medical Centre Hospital located in Jakarta were enrolled for the period of one year (the duration of the research). Out of this investigation, it has been discovered that there is a complex variation in the activity and degree of the transformations that occurred in the gastric mucosa among the Japanese and Indonesia patients who underwent the study and tested positive for Helicobacter pylori. These discoveries may mean that the Indonesian and the Japanese population affected by the Helicobacter pylori infection present different responses to the infections.

The scientists who underwent this investigation think that agents that appear and affect people`s way of living and their genetic history are essential elements that trigger the “Asian paradox”. However, further researches need to be done in order to gather more information and knowledge about this matter and thus, to better understand the variations in patients suffering from infections with the Helicobacter pylori.

The MASCOT project was financed in part by the European Commission (IST-027652).

This device is the first of its kind because it comprises various significant preparation phases for samples and muxing based detection which was created and implemented in the lab-on chip. An interesting fact is that all the module complexes for investigating and mingling with the samples and the detection feature of the gadget are preparing to be even further minimized in order to be incorporated in just one lab-on-chip device. The researchers desire that this complex would become feasible in a medical manner in the Oslo during the studies of breast cancer treatments.

A great thing is that this circulating cancer diagnosis represents an important methodology for a personalized tracking of people who suffer from malignant tumors both in an early development stage and in an advanced one. This, in turn, would lead to an improvement in the physicians and surgeons` decision-making ability.

Taking into consideration breast cancer, 5 milliliters of blood comprise just two or three cells coming from tumors. In order to find out from the blood tests if someone has developed malignant tumors, the malignant cells circulating in the blood flow have to be isolated, caught and their genetics have to be observed.

The nowadays diagnostics done in the labs of the medical facilities are not time- and cost-effective and require a lot of work. This type of diagnosis might ask for a number of processing phases for the sample in various medical tools so the complete analysis of the sample is for sure to take more than 24 hours. On the other hand, the lab-on-chip technology could have many benefits for the entire medical world and the people who are ill. This innovative system is cost-effective, has easy usage and is very fast compared to the past methods. An interesting aspect of this technology is that it does not need medical laboratories and laborious hours. Instead, the tests comprised by the lab-on-chip can be undergone routinely either in the physician`s office or nearby the bed of the sick person. Thus, the lab-on-chip technology represent a time saving opportunity which does not require laborious work do be done in order to get the results to diagnosis tests. Moreover, it provides the minimum of body invasion in order to discover cancer cells and a customized treatment and screening.

The study`s collaborators created a modular platform in which every module performed a specific job and kept its independence. This endowment means that the technology can be utilized in numerous medical tests. The first module of the platform is the incubation one which has the role of mixing the blood under testing with specialized magnetic beads in order to link the tumor cells to one another. The second module has the role to isolate the malignant cells and count them thanks to a magnetic characteristic which can attract each cell and dielectrophoresis function. The third one is entitled the amplification module. It has the role to destroy the wall comprising malignant cells and by doing this the mRNA, the desired genetic material, is taken out from the sample and enhanced by using MLPA (multiplex ligation dependent probe amplification).

In the third module, certain procedures that measure the biochemical substances from the extracted substance enhance approximately twenty markers that are generated in the carcinoma cells of the breast. In the last module used for detection, the enhanced genetic substance is discovered by utilizing a series of electrochemical markers. These modules have been created and are feasible to use on the samples of blood.

The modules are prepared for advanced incorporation in just one lab-on-chip. By minimizing the size and linking the micofluidic and electronic functions of the technology, their accuracy and trustworthy character is enhanced in order to perform tests on sick people. The medical utilization of the lab-on-chip is going to be observed in order to see its similarities and differences compared to the existing methodologies used in the breast cancer treatments. This is going to be accomplished by a new investigation.

D2 vitamin represents a food supplement for preventing and treating deficiency of vitamin D both for adults and children. If the patient desires to extend the duration of his or her D2 treatment for let`s say a period of just one week after the first decisive two months up to six years after them, the person just prevents the deficiency of vitamin D but with no adverse side-effects that could threaten his or her health.

The investigation undergone by researchers from Boston University School of Medicine is released on the Internet in the Archives of Internal Medicine journal. The research was led by Michael Holick who is the director of the Bone Healthcare Clinic Vitamin D, Skin and Bone Research Laboratory within the Boston University School of Medicine

Vitamin D is an important element in developing stronger bone mass due to the fact that it stimulated the organism to assimilate phosphorus and calcium from the food one eats or from exposure to the natural sunlight. The deficiency of vitamin D may trigger rickets in kids and the osteomalacia condition which represents a very painful illness in adults. This type of deficiency may also stimulate the appearance of osteoporosis and has also been associated with an enhanced predisposition of heart disease, autoimmune diseases, cancer, diabetes and viral illnesses comprising influenza.

The team of investigators focused on a sample of 86 patients. 41 of the people with vitamin D deficiency had to take for a period of two months 50,000 International Units of vitamin D2 on a weekly basis before commencing maintenance treatment. For this group, the average prior to treatment level of 25(OH)D (25-hydroxyvitamin D status) was of 19 ng/ml. After the two months of treatment, this initial level increased to 37 ng/ml. After this, this group of patients received a treatment of 50,000 International Units of vitamin D2 once every two weeks and recorded an average final level of 25-hydroxyvitamin D status of 47 ng/ml.

The remaining 45 people took just maintenance treatment comprising intakes of 50,000 International Units of vitamin D2 once every two weeks. They recorded a prior-to-treatment average level of 25-hydroxyvitamin D status of 27 ng/ml and afterwards, a final average of 47 ng/ml.

As Michael Holick who is director of the General Clinical Research Unit and teacher of medicine, physiology and biophysics within Boston University School of Medicine, also, states taking vitamin D2 brings a positive outcome because it increases the levels of 25-hydroxyvitamin D status if it is taken in physiologic and pharmacologic dosage. In treatments against deficiencies of vitamin D, if patients take lager doses of vitamin D2 they should stay calm because they have no adverse effects.

This investigation represents the first of its kind that proves just how effective the treatment with vitamin D2 in counteracting vitamin D deficiency, over the long-term and as a continuous practice.

In order to complete the research, the multi-organizational group of investigators observed the telomeres of Arabidopsis which is a weed located everywhere around the Globe and found out that it contains a set of proteins that people did not know anything about. After this discovery, the investigators found its human correspondent. This result might prove to be advantageous for comprehending better the nature of cancer and cell`s life span. The investigation`s findings were released in the Molecular Cell journal. The research was financed by the National Institutes of Health.

Professor of biophysics and biochemistry within Texas A&M University, Mrs. Dorothy Shippen and Carolyn Price, her counterpart from the University of Cincinnati College of Medicine, professor of cell biology and cancer, were the co-authors of this investigation.

The telomeres are found in the chromosomes in their every end and comprise DNA and protein. Their primary role is to defend their location and are also essential factors regarding the cellular division process. Scientists also think that telomeres are essential elements in the lifetime duration of the cells.

As Dorothy Shippen states the team of researchers discovered that by removing the telomere proteins from the common weed, its chromosomes would join their ends in an aggressive manner, a process which would trigger significant problems in the Arabidopsis` evolution.

The investigation team proved that by removing just one human protein from the human malignant cells would cause a great DNA defect and the whole loss of some of the telomeres. In addition, the researchers state that they knew that the telomeres were a protective hat for the chromosomes which were a must in inhibiting the chromosomal fusions. Moreover, their length determines the cell`s division number. Nonetheless, the scientists still do not completely comprehend the way the hat structure prevents the chromosomal fusions or how it sets the length of the telomeres. These are considered very important issues due to the fact that if the telomeres are not maintained properly, illnesses like pulmonary fibrosis, premature aging syndromes, aplastic anemia and cancer could develop. The team of investigators aims to find a new protein complex which is needed in order to keep the benefic telomere hat on the chromosomes and they hope that this would lead the way for innovative studied associated with the illnesses affecting human beings.

The common weed, Arabidopsis, is present all over the Globe and is part of the cabbage, radish and mustard plant family of plants. Due to its genetic architecture, the Arabidopsis has been long studied as a standard “lab plant” in researches related to the cells and molecules coming from plants with flowers.

The multi-organizational investigation group states that their discoveries pave the way for new researches, which could end up with an innovative finding regarding the telomeres.

As one of the leading authors explains, future study in this matter would bring more knowledge regarding the telomeres` composition and their functionality. This, in turn, would provide scientists with a chance in finding the precise roles of the telomeres as guardians of the human beings` DNA. In addition, the future research could present the big picture of the manner in which damages to the telomeres inhibit the division process of the cells. Having discovered that the proteins act as essential actors in the DNA replication in the end of the chromosomes, the investigators suggest that new investigations should be undergone in order to gain more knowledge about just how the guardian hats function during the cellular division. As a conclusion, one of the leading investigators states that all these issues have to lead to answers in order to gather a complete understanding of the telomeres` roles in human beings.

The COX-2 (Cyclooxgenase-2) represents an enzyme which synthesizes prostaglandin. An evolved expression of Cyclooxgenase-2 is found in a great variety of malignant tumors affecting human beings which also comprise the gastric cancer. Experiments done on animals revealed that a long-term treatment with medication that inhibits the gastric carcinogenesis related to Cyclooxgenase-2. However, using such inhibiting drugs on humans is still not done due to the fact that the medication can trigger harmful and even fatal cardiovascular side-effects. This is why it is of great importance to discover the best and harmless therapy comprising Cyclooxgenase-2 inhibiting medications that also inhibit the Helicobacter pylori linked to gastric carcinogenesis.

A recent study regarding this matter was released in the World Journal of Gastroenterology in the October edition. Professor Wu coming from the Department of Gastroenterology within the Kaohsiung Medical University Hospital was the leader of the investigation. He utilized the Mongolian gerbil model in order to observe the best point of Cyclooxgenase-2 inhibiting medication for inhibiting gastric carcinogenesis produced by Helicobacter pylori. This new research also takes a closer look at the chemotherapy use for preventing this condition and also at the adverse effects the Cyclooxgenase-2 inhibiting medication may produce to the human body.

Earlier investigations utilized chemotherapies on a long-run basis for preventing the gastric carcinogenesis. Nonetheless, the Cyclooxgenase-2 inhibiting drugs did not come in placebo format and affected the patients. This group of medications must not be utilized on a long-run basis in the chemoprevention of the gastric malignant tumors.

As the investigation pointed, Celecoxib is a drug which might trigger anti-oncogenic effects. It can also inhibit the angiogenesis and the spreading of malignant tumors in the whole body. Moreover, this medication proved to be efficient in obtaining these effects either if it was used on a short- or a long- term basis. Celecoxib acted as a guardian who connotes an early oncogenic stage and not an inflammatory one. In addition, the utilization on short-term of Celecoxib proved to bring harmless inflammations and also stopped the spreading of gastric malignant cells in the organism.

If we were to listen to what the investigation has to say, the short- and long-term use of Celecoxib for counteracting Helicobacter pylori` infection pathway in a medical case is the best thing to do. This finding has been never present in earlier researches. Thus, the new discovery is essential in diminishing the adverse effects produced by Cyclooxgenase-2 inhibiting drugs.

The team of investigators state that Cyclooxgenase-2 inhibiting medication might be utilized as a chemoprevention treatment for patients that are 40 years or older. This approach may prove to play an essential part in the life of patients who suffer from extended metaplastic gastritis with an enhanced predisposition of developing gastric malignant tumors. Moreover, the therapy is essential also for people who suffer from refractory Helicobacter pylori infections with an increased predisposition for gastric malignant tumors.

As a gastroenterological specialist stated the research outcome provides new insights into a customized treatment against gastric malignant tumors starting with the prevention phase and also it may bring advantages for medical therapy in the near future.
.